As estrogen receptor (ER) signalling is crucial for breast cancer progression, ER‐positive breast cancer carcinomas are responsive to anti‐hormones such as Tamoxifen, for treatment of ER+ breast cancer. Here, ESR1 is linked to breast carcinoma.